Search Results

You are looking at 101 - 110 of 522 items for :

  • Refine by Access: All content x
Clear All
Free access

Marina Bagnoli, Federico Ambrogi, Silvana Pilotti, Paola Alberti, Antonino Ditto, Mattia Barbareschi, Enzo Galligioni, Elia Biganzoli, Silvana Canevari, and Delia Mezzanzanica

sufficient to eradicate the tumor, which often spreads into the peritoneal cavity. In the attempt to eradicate residual disease, patients receive a platinum-based therapy. After an initial response to front-line chemotherapy, the patients frequently relapse

Free access

Hiroko Yamashita, Mariko Nishio, Tatsuya Toyama, Hiroshi Sugiura, Naoto Kondo, Shunzo Kobayashi, Yoshitaka Fujii, and Hirotaka Iwase

cancer patients who received first-line treatment with endocrine therapy on relapse ( Yamashita et al . 2005 ). Our results indicated that patients whose primary breast tumors showed high phosphorylation of ERα Ser167, but not ERα Ser118, responded

Free access

S Leskelä, E Honrado, C Montero-Conde, I Landa, A Cascón, R Letón, P Talavera, J M Cózar, A Concha, M Robledo, and C Rodríguez-Antona

human prostate samples Prostate sample Age (years) Tissue Gleason score T stage a Relapse b CYP3A5 genotype a Tumor clinical classification corresponds to the 6th edition of the AJCC/UICC TNM classification of malignant tumors. b After surgery, PSA

Free access

Tanya K Day and Tina Bianco-Miotto

potentially curable by surgery and/or radiotherapy. However, up to 20% of patients will relapse with metastatic disease within 5–10 years. The main therapy for patients with locally advanced or metastatic disease targets androgen production and its receptor

Free access

Nelson Rangel, Milena Rondon-Lagos, Laura Annaratone, Simona Osella-Abate, Jasna Metovic, Maria Piera Mano, Luca Bertero, Paola Cassoni, Anna Sapino, and Isabella Castellano

, respectively, and to evaluate the potential differences in the variable distribution among the groups. The disease-free interval (DFI) was calculated from the date of surgical excision of the primary tumour to the date of the first relapse or last check

Free access

Penn Muluhngwi and Carolyn M Klinge

significant increase in disease-free survival ( Cuzick et al . 2010 , Regan et al . 2011 ). Unfortunately, the effectiveness of TAM and AI therapy is limited, as seen in the relapse of ∼40% of patients ( 1998 ). When resistance occurs, it is unclear which

Free access

R I Nicholson, C Staka, F Boyns, I R Hutcheson, and J M W Gee

to effective treatment of breast cancer. Thus, to date, improvement in relapse-free survival in the adjuvant setting observed with AIs versus tamoxifen remains modest. Moreover, not all patients who are treated with AIs respond equally well, while

Free access

Marion T Weigel and Mitch Dowsett

prognosis has occurred. While this almost certainly also contributes to improved outcomes, it also poses a challenge for clinicians regarding the choice of optimal adjuvant treatment. The relapse rate after surgery alone in patients detected with early

Open access

Kristina Warton, Kate L Mahon, and Goli Samimi

following surgery and none of these four subjects experienced relapse. Conversely, of the remaining 12 who did have detectable ctDNA, all but one experienced relapse ( Diehl et al . 2008 ). The above study was based on mutations and used a highly

Free access

Zaid Al-Qurayshi, Mohamed A Shama, Gregory W Randolph, and Emad Kandil

-012-1518-z ) Ito Y Tomoda C Uruno T Takamura Y Miya A Kobayashi K Matsuzuka F Kuma K Miyauchi A 2006a Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid